miércoles, 18 de septiembre de 2019

Why immunotherapy fails 60% of metastatic melanoma patients - ISRAEL21c

Why immunotherapy fails 60% of metastatic melanoma patients - ISRAEL21c

Israel21c



#ProteinMapping

Why immunotherapy fails 60% of metastatic melanoma patients

Israeli study reveals the reason that some cancer patients don’t respond to immunotherapy.

 SEPTEMBER 17, 2019, 8:40 AM
Brian Blum
Brian has been a journalist and high-tech entrepreneur for over 20 years. He combines this expertise for ISRAEL21c as he writes about hot new local startups, pharmaceutical advances, scientific discoveries, culture, the arts and daily life in Israel. He loves hiking the country with his family (and blogging about it). Originally from California, he lives in Jerusalem with his wife and three children.

No hay comentarios:

Publicar un comentario